ALKS · earnings call history
Alkermes Q2 FY26 — Orexin Platform Leadership and Commercial Strength
Read the briefAlkermes Q1 FY26 — Strong Commercial Performance and Strategic Acquisition
Read the briefAlkermes Q4 FY25 — Strong Commercial Performance and Orexin Pipeline Advancement
Read the briefBrowse all US companies on the earnings-call register.